CDKN1A and cancer: Cell cycle progression, where the CDKN1 proteins act as natural inhibitors may be functionally linked via pVHL to the HIF-1α and HIF-2α-dependent pathways, i.e. hypoxia/angiogenesis response, which is particularly relevant in cancer development.